{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:37:25Z","timestamp":1785515845904,"version":"3.56.0"},"reference-count":69,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the overexpression of CD123 and CD303 surface antigens. These molecular markers play a crucial role in diagnosing diseases and developing targeted therapies. Traditional treatment options for BPDCN have demonstrated limited effectiveness, highlighting the need for new and innovative therapeutic strategies. Recent advances in immunotherapy, particularly therapeutic monoclonal antibodies, bispecific T-cell engagers, and CAR T-cell therapy, have provided promising alternatives. Tagraxofusp, the first FDA-approved CD123-targeted therapy, has significantly improved patient outcomes. Additionally, emerging CD303-targeting strategies offer the potential for further advancements. Despite these breakthroughs, challenges such as treatment resistance and toxicity remain. This review explores the latest developments in BPDCN treatment, emphasizing the potential of CD123 and CD303 as targets for precision medicine interventions. The ongoing evolution of targeted immunotherapies holds promise for improving patient survival and redefining treatment paradigms in hematologic malignancies.<\/jats:p>","DOI":"10.3390\/ijms26062732","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T07:20:00Z","timestamp":1742282400000},"page":"2732","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5613-9149","authenticated-orcid":false,"given":"Domenico","family":"Galati","sequence":"first","affiliation":[{"name":"Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Onco-Hematology and Innovative Diagnostics, Istituto Nazionale Tumori\u2014IRCCS\u2014Fondazione G. Pascale, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4917-2076","authenticated-orcid":false,"given":"Serena","family":"Zanotta","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Onco-Hematology and Innovative Diagnostics, Istituto Nazionale Tumori\u2014IRCCS\u2014Fondazione G. Pascale, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Florio","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Onco-Hematology and Innovative Diagnostics, Istituto Nazionale Tumori\u2014IRCCS\u2014Fondazione G. Pascale, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5717-0911","authenticated-orcid":false,"given":"Sara","family":"Mele","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Onco-Hematology and Innovative Diagnostics, Istituto Nazionale Tumori\u2014IRCCS\u2014Fondazione G. Pascale, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7899-3071","authenticated-orcid":false,"given":"Rosaria","family":"De Filippi","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Universit\u00e0 degli Studi di Napoli Federico II, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9425-9026","authenticated-orcid":false,"given":"Antonio","family":"Pinto","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Onco-Hematology and Innovative Diagnostics, Istituto Nazionale Tumori\u2014IRCCS\u2014Fondazione G. Pascale, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.2012.072645","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: An Italian multicenter study","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.critrevonc.2016.10.006","article-title":"Dendritic cells in hematological malignancies","volume":"108","author":"Galati","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/eji.201040501","article-title":"Development and homeostasis of dendritic cells","volume":"40","author":"Liu","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5045\/br.2023.2023052","article-title":"Plasmacytoid dendritic cell neoplasms","volume":"58","author":"Lee","year":"2023","journal-title":"Blood Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2141.2006.06458.x","article-title":"Plasmacytoid dendritic cell leukaemia\/lymphoma: Towards a well defined entity?","volume":"136","author":"Feuillard","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"19204","DOI":"10.18632\/oncotarget.4146","article-title":"Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile","volume":"6","author":"Lopez","year":"2015","journal-title":"Oncotarget"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.bmt.1704215","article-title":"What is CD4+CD56+ malignancy and how should it be treated?","volume":"32","author":"Reimer","year":"2003","journal-title":"Bone Marrow Transpl."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2009.07679.x","article-title":"Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia","volume":"145","author":"Feuillard","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood.2020007897","article-title":"Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia","volume":"137","author":"Xiao","year":"2021","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjh.14146","article-title":"Blastic plasmacytoid dendritic cell neoplasm: Diagnostic criteria and therapeutical approaches","volume":"174","author":"Pagano","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_11","first-page":"401","article-title":"Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells","volume":"5","author":"Mezzanzanica","year":"1998","journal-title":"Cancer Gene Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Testa, U., Pelosi, E., and Castelli, G. (2019). CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. Cancers, 11.","DOI":"10.3390\/cancers11091358"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cyto.a.22628","article-title":"Single-cell mass cytometry reveals intracellular survival\/proliferative signaling in FLT3-ITD-mutated AML stem\/progenitor cells","volume":"87","author":"Han","year":"2015","journal-title":"Cytom. A"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.4049\/jimmunol.173.7.4433","article-title":"Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells","volume":"173","author":"Moseman","year":"2004","journal-title":"J. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-417028-5.00001-6","article-title":"Ontogeny and functional specialization of dendritic cells in human and mouse","volume":"120","author":"Haniffa","year":"2013","journal-title":"Adv. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Dai, H., Thomson, A.W., and Rogers, N.M. (2019). Dendritic Cells as Sensors, Mediators, and Regulators of Ischemic Injury. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02418"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3324\/haematol.2020.247569","article-title":"Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm","volume":"106","author":"Wang","year":"2021","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ajh.24258","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy","volume":"91","author":"Deotare","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1182\/bloodadvances.2019000647","article-title":"How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?","volume":"3","author":"Vidal","year":"2019","journal-title":"Blood Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/107327481402100404","article-title":"Blastic plasmacytoid dendritic cell neoplasm: Update on molecular biology, diagnosis, and therapy","volume":"21","author":"Riaz","year":"2014","journal-title":"Cancer Control"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Sapienza, M.R., Pileri, A., Derenzini, E., Melle, F., Motta, G., Fiori, S., Calleri, A., Pimpinelli, N., Tabanelli, V., and Pileri, S. (2019). Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects. Cancers, 11.","DOI":"10.3390\/cancers11050595"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102928","DOI":"10.1016\/j.critrevonc.2020.102928","article-title":"New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm","volume":"149","author":"Zhang","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.hoc.2020.01.004","article-title":"CD123 as a Therapeutic Target Against Malignant Stem Cells","volume":"34","author":"Sugita","year":"2020","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-065X.2012.01164.x","article-title":"The GM-CSF\/IL-3\/IL-5 cytokine receptor family: From ligand recognition to initiation of signaling","volume":"250","author":"Broughton","year":"2012","journal-title":"Immunol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/10428194.2017.1361023","article-title":"Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia","volume":"59","author":"Cruz","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/0092-8674(90)90341-B","article-title":"Chimeric immunoglobulin-T cell receptor proteins form functional receptors: Implications for T cell receptor complex formation and activation","volume":"60","author":"Goverman","year":"1990","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","article-title":"Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients","volume":"124","author":"Frankel","year":"2014","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1080\/10428194.2022.2042685","article-title":"Tagraxofusp as first-line treatment for blastic plasmacytoid dendritic cell neoplasm","volume":"63","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood.V130.Suppl_1.797.797","article-title":"Resistance to SL-401 in AML and BPDCN Is Associated with Loss of the Diphthamide Synthesis Pathway Enzyme DPH1 and Is Reversible By Azacitidine","volume":"130","author":"Stephansky","year":"2017","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","article-title":"Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1172\/JCI128571","article-title":"DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance","volume":"129","author":"Togami","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1182\/blood-2021-147486","article-title":"Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN","volume":"138","author":"Lane","year":"2021","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/bloodadvances.2023011721","article-title":"Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia","volume":"8","author":"Lane","year":"2024","journal-title":"Blood Adv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3324\/haematol.2018.205252","article-title":"CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia","volume":"104","author":"Angelova","year":"2019","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: A phase 1\/2 study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1538-7445.AM2024-3129","article-title":"BYON4413, an in vivo active CD123-targeting antibody-drug conjugate, combines effectively with azacitidine and venetoclax in acute myeloid leukemia cell lines","volume":"84","author":"Hersmus","year":"2024","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1182\/blood-2023-177622","article-title":"Potent in Vitro and In Vivo Efficacy of BYON4413, a Duba-Based Antibody-Drug Conjugate Targeting CD123 in Acute Myeloid Leukemia","volume":"142","author":"Kappers","year":"2023","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/s41375-019-0645-z","article-title":"Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents","volume":"34","author":"Kubasch","year":"2020","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","article-title":"Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: Results from a multicenter, randomized, phase 2\/3 study","volume":"35","author":"Montesinos","year":"2021","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Bole-Richard, E., Pemmaraju, N., Cael, B., Daguindau, E., and Lane, A.A. (2022). CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers, 14.","DOI":"10.3390\/cancers14092287"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Pelosi, E., Castelli, G., and Testa, U. (2023). CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032718"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Zanotta, S., Galati, D., De Filippi, R., and Pinto, A. (2024). Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202401.0460.v1"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1158\/1538-7445.AM2019-LB-199","article-title":"APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR\u2122 molecule for redirected T-cell cytotoxicity with limited cytokine release, is well tolerated in repeat dose toxicology studies in cynomolgus macaques","volume":"79","author":"Comeau","year":"2019","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1158\/1535-7163.TARG-17-B111","article-title":"Characterization of APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR\u2122 molecule for redirected T-cell cytotoxicity, in preclinical models of AML and nonhuman primates","volume":"17","author":"Comeau","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1158\/1538-7445.AM2018-1786","article-title":"APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR\u00ae molecule for redirected T-cell cytotoxicity, induces potent T-cell activation, proliferation and cytotoxicity with limited cytokine release","volume":"78","author":"Comeau","year":"2018","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1038\/s41375-020-0777-1","article-title":"CD28\/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm","volume":"34","author":"Fredon","year":"2020","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/s41467-022-29669-8","article-title":"Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells","volume":"13","author":"Cai","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.omto.2020.04.009","article-title":"Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.hoc.2020.01.006","article-title":"Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm","volume":"34","author":"Xue","year":"2020","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s43152-024-00055-4","article-title":"The Role of Cancer-Specific Target Antigens in CAR T Cell Therapy in Hematological Malignancies","volume":"5","author":"Khan","year":"2024","journal-title":"Curr. Tissue Microenviron. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s43152-024-00053-6","article-title":"Comprehensive Review on the Effect of Stem Cells in Cancer Progression","volume":"5","author":"Das","year":"2024","journal-title":"Curr. Tissue Microenviron. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1182\/blood-2010-02-258558","article-title":"Nomenclature of monocytes and dendritic cells in blood","volume":"116","author":"Ancuta","year":"2010","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.immuni.2014.04.016","article-title":"Development and function of dendritic cell subsets","volume":"40","author":"Mildner","year":"2014","journal-title":"Immunity"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Diebold, S.S. (2009). Activation of dendritic cells by toll-like receptors and C-type lectins. Handbook of Experimental Pharmacology, Springer.","DOI":"10.1007\/978-3-540-71029-5_1"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/10428194.2021.1975192","article-title":"CD303 (BDCA-2)\u2014A potential novel target for therapy in hematologic malignancies","volume":"63","author":"Wilson","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"El Hussein, S., and Wang, W. (2024). Flow Cytometry Profiling of Plasmacytoid Dendritic Cell Neoplasms. Cancers, 16.","DOI":"10.3390\/cancers16112118"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e32904","DOI":"10.1097\/MD.0000000000032904","article-title":"Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review","volume":"102","author":"Wang","year":"2023","journal-title":"Medicine"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Wang, W., Xu, J., Khoury, J.D., Pemmaraju, N., Fang, H., Miranda, R.N., Yin, C.C., Hussein, S.E., Jia, F., and Tang, Z. (2022). Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers, 14.","DOI":"10.3390\/cancers14143375"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"464","DOI":"10.15252\/emmm.201404719","article-title":"Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms","volume":"7","author":"Pellerin","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI124466","article-title":"Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus","volume":"129","author":"Furie","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/19420862.2018.1451283","article-title":"Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern","volume":"10","author":"Fournier","year":"2018","journal-title":"mAbs"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Janovec, V., Aouar, B., Font-Haro, A., Hofman, T., Trejbalova, K., Weber, J., Chaperot, L., Plumas, J., Olive, D., and Dubreuil, P. (2018). The MEK1\/2-ERK Pathway Inhibits Type I IFN Production in Plasmacytoid Dendritic Cells. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00364"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood-2012-07-442590","article-title":"TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/6\/2732\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:55:55Z","timestamp":1760028955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/6\/2732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":69,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ijms26062732"],"URL":"https:\/\/doi.org\/10.3390\/ijms26062732","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]}}}